新型低密度脂蛋白胆固醇评估方法对非高密度脂蛋白胆固醇和载脂蛋白B次级目标效用的影响
更准确估算LDL-C后,指南建议的非HDL-C目标仅对少数人改变管理,apoB目标在达到胆固醇目标后效用有限。
要点
- 更准确估算LDL-C后,非HDL-C目标仅对约2%的人有额外管理价值。
- 达到LDL-C和non-HDL-C双目标后,仅0-1%的人apoB仍超目标。
- Friedewald估算会高估非HDL-C和apoB未达标比例,尤其在高危人群。
核心结论
- 更准确估算LDL-C后,指南建议的非HDL-C目标仅对少数个体(包括冠心病等高危特征者)可改变管理。
- 达到胆固醇目标后,当前指南建议的apoB目标提供有限效用。
研究设计与样本
- 使用Friedewald估算(LDL-CF)和新型更准确方法(LDL-CN)评估LDL-C,并检查非HDL-C和apoB目标达标情况。
主要发现
- 7%-9%和31%-36%的个体分别LDL-C<70和<100 mg/dL。
- LDL-CF<70 mg/dL者中14%-15%非HDL-C≥100 mg/dL,7%-8% apoB≥80 mg/dL;LDL-CF<100 mg/dL者中8%-10%非HDL-C≥130 mg/dL,2%-3% apoB≥100 mg/dL。
- LDL-CN<70或100 mg/dL者中仅约2%和约1%非HDL-C和apoB超目标。
- 高危特征者中,LDL-CN<70 mg/dL者约0%-3%非HDL-C≥100或apoB≥80 mg/dL,而LDL-CF<70者分别为13%-38%和9%-25%。
- LDL-CF或LDL-CN<70且非HDL-C<100 mg/dL者中0%-1% apoB≥80 mg/dL;双<100和<130 mg/dL者中0%-0.4% apoB≥100 mg/dL。
关键数值与推荐
- LDL-C目标:<70 mg/dL(极高危)和<100 mg/dL(高危)。
- 非HDL-C目标:<100 mg/dL(极高危)和<130 mg/dL(高危)。
- apoB目标:<80 mg/dL(极高危)和<100 mg/dL(高危)。
临床怎么用
- 采用更准确LDL-C估算方法后,非HDL-C和apoB次级目标仅对极少数患者提供额外管理信息。
- 临床可优先关注LDL-C达标,非HDL-C和apoB作为次级目标的价值在准确估算LDL-C后有限。
局限性
- 研究为横断面分析,不能推断因果关系。
- 结果基于特定人群和估算方法,外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Selected dyslipidemia guidelines recommend non-high-density lipoprotein-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as secondary targets to the primary target of low-density lipoprotein-cholesterol (LDL-C). After considering 2 LDL-C estimates that differ in accuracy, we examined: (1) how frequently non-HDL-C guideline targets could change management; and (2) the utility of apoB targets after meeting LDL-C and non-HDL-C targets. METHODS: We analyzed 2518 adults representative of the US population from the 2011 to 2012 National Health and Nutrition Examination Survey and 126 092 patients from the Very Large Database of Lipids study with apoB. We identified all individuals as well as those with high-risk clinical features, including coronary artery disease, diabetes mellitus, and metabolic syndrome who met very high- and high-risk guideline targets of LDL-C <70 and <100 mg/dL using Friedewald estimation (LDL-CF) and a novel, more accurate method (LDL-CN). Next, we examined those not meeting non-HDL-C (<100, <130 mg/dL) and apoB (<80, <100 mg/dL) guideline targets. In those meeting dual LDL-C and non-HDL-C targets (<70 and <100 mg/dL, respectively, or <100 and <130 mg/dL, respectively), we determined the proportion of individuals who did not meet guideline apoB targets (<80 or <100 mg/dL). RESULTS: A total of 7% to 9% and 31% to 36% of individuals had LDL-C <70 and <100 mg/dL, respectively. Among those with LDL-CF<70 mg/dL, 14% to 15% had non-HDL-C ≥100 mg/dL, and 7% to 8% had apoB ≥80 mg/dL. Among those with LDL-CF<100 mg/dL, 8% to 10% had non-HDL-C ≥130 mg/dL and 2% to 3% had apoB ≥100 mg/dL. In comparison, among those with LDL-CN<70 or 100 mg/dL, only ≈2% and ≈1% of individuals, respectively, had non-HDL-C and apoB values above guideline targets. Similar trends were upheld among those with high-risk clinical features: ≈0% to 3% of individuals with LDL-CN<70 mg/dL had non-HDL-C ≥100 mg/dL or apoB ≥80 mg/dL compared with 13% to 38% and 9% to 25%, respectively, in those with LDL-CF<70 mg/dL. With LDL-CF or LDL-CN<70 mg/dL and non-HDL-C <100 mg/dL, 0% to 1% had apoB ≥80 mg/dL. Among all dual LDL-CF or LDL-CN<100 mg/dL and non-HDL-C <130 mg/dL individuals, 0% to 0.4% had apoB ≥100 mg/dL. These findings were robust to sex, fasting status, and lipid-lowering therapy status. CONCLUSIONS: After more accurately estimating LDL-C, guideline-suggested non-HDL-C targets could alter management in only a small fraction of individuals, including those with coronary artery disease and other high-risk clinical features. Furthermore, current guideline-suggested apoB targets provide modest utility after meeting cholesterol targets. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01698489.
引用
- Sathiyakumar V, Park J, Quispe R, et al. Impact of Novel Low-Density Lipoprotein-Cholesterol Assessment on the Utility of Secondary Non-High-Density Lipoprotein-C and Apolipoprotein B Targets in Selected Worldwide Dyslipidemia Guidelines. Circulation. 2018. PMID: 29506984. doi:10.1161/CIRCULATIONAHA.117.032463
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。